IMNN press release
Key Highlights
- ➤IMNN-001 OVATION 3 enrollment expected to complete by Q1 2029
- ➤IMUNON reported Q3 net loss $3.8 million, or $0.64 per share
- ➤IMUNON held $4.0 million cash and $5.0 million restricted cash
- ➤ThermoDox rights sale could deliver up to $16.5 million milestone payments
- ➤$1.2 million debt exchange reduced A-1 Note balance approximately 43%
Expert Statements
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON
“IMUNON continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON
“The data generated to date, our collaboration with the National Cancer Institute, and the favorable safety profile observed across studies support the ongoing advancement of the program and its potential to provide a transformative treatment for women with this difficult disease.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON
“We believe the OVATION 3 study is well positioned, with a broad patient population, two planned interim analyses, and a development strategy designed to support efficient execution and evaluation of the treatment’s potential benefit.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON
“We have also taken steps to continue to sharpen our strategic focus and strengthen IMUNON’s financial position.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON
“Through our agreement to transition ThermoDox(®) to a dedicated development partner and our recent debt-for-equity exchange, we are demonstrating the disciplined approach to capital allocation that we believe is essential to advancing our most significant clinical opportunity while preserving opportunities for future value creation.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON
“As we look ahead, our priorities remain clear: execute OVATION 3, build on the growing body of evidence supporting IMNN-001 and advance a potentially transformative new treatment option for women who urgently need better outcomes.”
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer
Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by the first quarter of 2029, supported by strong Phase 2 clinical data showing significant overall survival benefit
Get started
Create a free account to read the full story.